Salesforce stock wobbles after hours as Slackbot AI-agent rollout meets fresh software-sector nerves

Salesforce stock wobbles after hours as Slackbot AI-agent rollout meets fresh software-sector nerves

New York, Jan 14, 2026, 18:04 EST — After-hours

  • Salesforce shares dipped once more as investors digested the implications of AI agents for major subscription software.
  • The company is launching a redesigned Slackbot within Slack, promoting it as a “personal agent for work.”
  • Traders want proof that AI features boost revenue, not just increase expenses or reduce software “seats.”

Salesforce (CRM) shares dipped 0.6% during Wednesday’s regular session, trading near $239.57 in after-hours. The stock followed a broader selloff in big enterprise software names. Oracle slumped 4.3%, while ServiceNow dropped 2.6% by the close, according to MarketWatch data. 1

The small pullback came after Tuesday’s sharp selloff, when Salesforce plunged 6.5% as investors fretted that AI-driven productivity gains might shrink software subscriptions in the long run. Adobe took a hit that day as well, following an Oppenheimer downgrade. The takeaway was clear: AI features are real, but turning them into steady revenue remains a tough challenge. 2

Salesforce’s newest product launch arrives amid a tricky market environment. On Tuesday, the company announced the general availability of a revamped Slackbot for select Business+ and Enterprise+ clients, with the rollout set to continue in phases through January and February. “It’s the front door to the Agentic Enterprise,” said Slack CTO Parker Harris in the release. 3

TechCrunch revealed that the updated Slackbot can locate information, draft emails, and set up meetings within Slack. If users allow it, the bot also links to tools like Microsoft Teams and Google Drive. Harris told TechCrunch the name Slackbot stuck because it’s already widely recognized. 4

The timing isn’t random. A fresh surge of “agentic” tools — software that carries out a series of actions for users — has reignited the debate over whether apps lose their stickiness when work happens through a chat-style interface. Anthropic rolled out “Claude Cowork” this week, a research preview capable of accessing folders and running tasks within its macOS app, according to The Verge. 5

On Wall Street, some analysts say the gloom is outpacing the facts. Barclays’ Raimo Lenschow bumped his price target on Salesforce to $338 from $330 and maintained an Overweight rating. He noted that “Macro and IT spending are stable,” and pointed out that “stock valuation levels are low and the sector is out of favor,” according to a report from TheFly, cited by TipRanks. 6

A separate filing revealed that CEO Marc Benioff exercised a stock option for a single share at $215.17 on Jan. 13. Though the trade was minor, it caught attention amid a market quick to dissect insider moves and investor sentiment. 7

The risk scenario remains. If AI agents cut down the demand for per-user “seat” licenses—the usual subscription model charging by headcount—revenue growth might stall, even with strong customer interest. And if these AI add-ons don’t prove their value quickly, CIOs may just hold off.

Wednesday’s wider market dragged, with U.S. stocks sliding for a second straight day. Investors wrestled with mixed results from major banks alongside fresh economic figures, Reuters reported, feeding uneven risk appetite beyond just the software sector. 8

Investors are looking for early clues on whether the Slackbot rollout will boost paid adoption of Salesforce’s AI offerings, rather than just serving as a Slack feature update. Salesforce said enterprise admins can manage Slackbot access permissions through Feb. 10, a key date to gauge customer uptake. The company hasn’t announced its next earnings release yet, but MarketBeat projects the report will arrive on Feb. 25. 9

Stock Market Today

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
New York, Feb 7, 2026, 10:22 EST — Market closed. Eli Lilly and Company shares closed Friday up $37.34, or 3.7%, at $1,058.18. The move came as U.S. regulators sharpened their tone on “compounded” weight-loss drugs — pharmacy-made versions meant for shortages or special patient needs that have morphed into mass-market alternatives. The FDA said it would take action against telehealth firm Hims & Hers over a $49 pill it marketed as a Wegovy-like option, and Lilly said it “applauded” the agency’s action. 1 Why it matters now: obesity and diabetes medicines have become the growth engine for large drugmakers,
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

7 February 2026
Meta closed down 1.3% Friday at $661.46, capping a 6.4% weekly drop as investors questioned heavy AI spending. Amazon and Alphabet also fell after outlining major capital outlays. Meta’s Instagram suffered a brief outage this week. Legal risks persist, with trials involving Meta set for next week in Los Angeles and New Mexico.
Costco stock edges up as insiders file share sale disclosures ahead of shareholder vote
Previous Story

Costco stock edges up as insiders file share sale disclosures ahead of shareholder vote

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings
Next Story

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Go toTop